Key Points Eli Lilly has a deep pipeline in its core therapeutic area. Its next-gen obesity drug, retatrutide, posted excellent results in Phase 3 studies. The medicine could cement Eli Lilly's lead in the anti-obesity market. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE:LLY) is posting excellent financial results, with tirzepatide, a medicine that has earned indications for diabetes, weight management, and obstructive sleep apnea (OSA), currently the company's biggest growth driver. Tirzepatide was a breakthrough. It became the first approved therapy to mimic the actions of the GLP-1 and GIP gut hormones, a mechanism of action that likely contributes to its greater effectiveness than its biggest competitor, semaglutide.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.